Phase 1/2 study of ARV-110, an androgen receptor (AR) PROTAC degrader, in metastatic castration-resistant prostate cancer (mCRPC).

被引：106

作者：

Gao, Xin

Burris, Howard A., III

Vuky, Jacqueline

Dreicer, Robert

Sartor, A. Oliver

Sternberg, Cora N.

Percent, Ivor John

Hussain, Maha H. A.

Kalebasty, Arash Rezazadeh

Shen, John

Heath, Elisabeth I.

Abesada-Terk, Guillermo

Gandhi, Sunil G.

McKean, Meredith

Lu, Haolan

Berghorn, Elmer

Gedrich, Richard

Chirnomas, S. Debbie

Vogelzang, Nicholas J.

Petrylak, Daniel P.

机构：

[1] Massachusetts Gen Hosp, Boston, MA 02114 USA

[2] Sarah Cannon Res Inst & Tennessee Oncol, Nashville, TN USA

[3] Oregon Hlth & Sci Univ, Portland, OR 97201 USA

[4] Univ Virginia, Ctr Canc, Charlottesville, VA 22908 USA

[5] Tulane Canc Ctr, New Orleans, LA USA

[6] Weill Cornell Med, Englander Inst Precis Med, Hematol Oncol, New York, NY USA

[7] Florida Canc Specialists South, Port Charlotte, FL USA

[8] Northwestern Univ, Robert H Lurie Comprehens Canc Ctr, Chicago, IL USA

[9] Univ Calif Irvine Med Ctr, Orange, CA USA

[10] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA USA

[11] Wayne State Univ, Karmanos Canc Inst, Sch Med, Detroit, MI USA

[12] Florida Canc Specialists East, W Palm Beach, FL USA

[13] Florida Canc Specialists North, St Petersburg, FL USA

[14] Arvinas Inc, New Haven, CT USA

[15] Comprehens Canc Ctr Nevada, Las Vegas, NV USA

[16] Yale Sch Med, Smilow Canc Ctr, New Haven, CT USA

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 40卷 / 06期

关键词：

D O I：

10.1200/JCO.2022.40.6_suppl.017

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页数：3